{"classes":[{"categories":[{"measurements":[{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"85.0","upperLimit":"NA","value":"114.5"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"76.0","upperLimit":"NA","value":"346.5"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"58.0","upperLimit":"NA","value":"218.5"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG003","lowerLimit":"121.0","upperLimit":"NA","value":"261.0"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG004","lowerLimit":"33.0","upperLimit":"NA","value":"127.0"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG005","lowerLimit":"62.0","upperLimit":"NA","value":"177.0"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG006","lowerLimit":"23.0","upperLimit":"NA","value":"139.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"7"}],"units":"Participants"}],"description":"Overall survival is defined as the number days between the date of the first dose of treatment and the date of death. If no date of death is recorded the Overall Survival time is censored at the Last available visit date.\n\nPhase 2: To determine the overall survival (OS) time for subjects with solid tumours.\n\nSS1:To determine the overall survival (OS) time for subjects who received 60 mg/m2 of EDO-S101 during a 60-minute Infusion.\n\nSS2: To determine the overall survival (OS) time for subjects who received 80 mg/m2 of EDO-S101 during a 80-minute Infusion.","dispersionType":"90% Confidence Interval","groups":[{"description":"Overall survival (OS) time for patients with small cell lung cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG000","title":"Tinostamustine (EDO-S101) - Phase 2 SCLC Cohort"},{"description":"Overall survival (OS) time for patients with soft tissue sarcoma who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG001","title":"Tinostamustine (EDO-S101) - Phase 2 STS Cohort"},{"description":"Overall survival (OS) time for patients with triple-negative breast cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG002","title":"Tinostamustine (EDO-S101) - Phase 2 TNBC Cohort"},{"description":"Overall survival (OS) time for patients with ovarian cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG003","title":"Tinostamustine (EDO-S101) - Phase 2 OC Cohort"},{"description":"Overall survival (OS) time for patients with endometrial cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG004","title":"Tinostamustine (EDO-S101) - Phase 2 EC Cohort"},{"description":"Overall survival (OS) time for patients with solid tumour who received 60 mg/m2 of EDO-S101 administered over 1 hour.","id":"OG005","title":"Tinostamustine (EDO-S101) - Sub Study 1 (SS1)"},{"description":"Overall survival (OS) time for patients with solid tumour who received 80 mg/m2 of EDO-S101 administered over 80 minutes.","id":"OG006","title":"Tinostamustine (EDO-S101) - Sub Study 2 (SS2)"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): All patients who received at least 1 dose of trial treatment and had at least 1 post-baseline response evaluation.","reportingStatus":"POSTED","timeFrame":"From patient's first dose until first documented progression/start of subsequent anti-cancer therapy/death from any cause, whichever came first, up to 42 months.","title":"Overall Survival (OS) Time for Phase 2 and Sub Studies","type":"SECONDARY","unitOfMeasure":"Days"}